Haplogen’s novel antiviral target partnered with Evotec published in “Nature”
Evotec AG has announced a promising research result in the field of picornaviruses published in a scientific article by Dr Thijn Brummelkamp, the co-founder of Haplogen GmbH (“Haplogen”), a biotech company based in Vienna, Austria, that develops antiviral therapeutics in a co-owned partnership with Evotec.
The article, now available in the online edition of Nature (http://dx.doi.org/10.1038/nature21032), describes the work performed at Dr Brummelkamp’s laboratory at the Netherlands Cancer Institute.
The study revealed the unexpected role of a bacterial clearance pathway in the picornavirus life cycle and further demonstrated that a key enzyme used by the virus to evade clearance (PLA2G16) represents a first-in-class drug target for a broad range of picornaviruses.
29 June 2018
Brokerage Event for 2019 SC1 calls (Oslo)
21 June 2018
Bone Innovation Summit (Lübeck)